Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UCSF Spinout Calithera Biosciences Takes $40 Million First Round

This article was originally published in The Pink Sheet Daily

Executive Summary

The cancer-fighting drug researcher is developing methods of activating caspases, enzymes that induce programmed cell death.

You may also be interested in...

Financings Of The Fortnight: Do Larger Series A Rounds Mean Less Successful Exits?

A five-year review of Series A financings finds no negative correlation between the size of an A round and the likelihood of an investor exit. Plus news on recent financings by Veracyte, Calithera Biosciences, Spark Therapeutics and Versant Ventures.

In Warp Drive Deal, VCs Have A Potential Buyer – And Can Force A Sale

Third Rock launches a computation-heavy discovery firm aimed at natural products, with commitments worth up to $125 million in equity and other funding.

Seeking Drugs “Hidden In Microbes,” Third Rock Launches Warp Drive Bio

Sanofi has an option to acquire the start-up, which screens for drugs by studying the genomics of natural products – and its investors have an option to force a sale.

Related Content


Latest News



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts